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Background: A deregulated energy metabolism is a hallmark of malignant disease that offers possible future
targets for treatment. We investigated the prognostic value of the glycolytic enzymes glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) and pyruvate kinase type M2 (PKM2), mitochondrial β-F1-ATPase (ATP5B) and the
bioenergetic cellular (BEC) index in advanced ovarian cancer.
Methods: Fresh tumor samples were prospectively collected from 123 patients undergoing primary surgery for
suspected advanced ovarian cancer. Of these, 57 met the eligibility criteria; stage IIC-IV, serous or endometrioid
subtype, specimens containing ≥ 50% tumor cells and patients receiving platinum-based chemotherapy. An
adequate amount of mRNA could be extracted in all but one case, with a resultant study population of 56 patients.
Eighty-six percent of cases had serous tumors, and 93% were grade 2–3. GAPDH, PKM2 and ATP5B mRNA- and
protein expression was assessed by real-time PCR and immunohistochemistry. We estimated the association with
platinum-free interval (PFI) and overall survival (OS) by Cox proportional hazards models. Median follow-up was
60 months.
Results: High GAPDH mRNA levels (HR 2.1, 95% CI 1.0-4.5) and low BEC-index (HR 0.47, 95% CI 0.23-0.95) were both
independently associated with shorter PFI. Median PFI for patients with high GAPDH mRNA was 5.0 months
compared to 10.1 months for low expression cases (p = 0.031). Similarly, median PFI for patients with low BEC-index
based on mRNA was 5.3 months compared to 9.8 months for high BEC-index cases (p = 0.028).
Conclusions: High GAPDH or low BEC-index mRNA expression indicate early disease progression in advanced serous
ovarian cancer.
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Epithelial ovarian cancer (EOC) is a heterogeneous disease
comprising several subtypes with very different response
to treatment and prognosis. The majority of EOC-patients
are detected at advanced stage and the overall 5-year sur-
vival rate is 50% or less [1]. Treatment for primary EOC
consists of cytoreductive surgery and platinum-taxane
combination chemotherapy. Despite emerging knowledge
of subtype-specific variations in tumor biology and
chemo-responsiveness, EOC is still treated as one entity.
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reproduction in any medium, provided the ordiagnosed tumors. This subtype is, although often initially
platinum-sensitive, associated with a poor prognosis.
Identification of EOC subtype-specific prognostic markers
is important for development of new targeted therapies.
A reprogrammed energy metabolism has recently been
designated a “new” hallmark of cancer [2]. These metabolic
changes, including increased aerobic glycolysis, decreased
oxidative phosphorylation and increased glutaminolysis
and fatty acid-metabolism, are known features of cancer,
which often correlate with an overall poor prognosis [3,4].
Several glycolytic enzymes, for example glyceraldehyde
3-phosphate dehydrogenase (GAPDH) and pyruvate kinase
M2 (PKM2), have been reported overexpressed in cancer
[5-8]. First introduced by Cuezva and co-workers in 2002
[3], a bioenergetic cellular index (BEC-index), based on theLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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catalytic subunit of the rate-limiting enzyme of oxidative
phosphorylation), heat-shock protein 60 (HSP60, a mito-
chondrial chaperone), and glycolytic GAPDH, has been
shown to be of prognostic value in several cancer types
such as colon, lung and breast carcinomas [3,9,10]. The
expression of above metabolic markers has not yet been
studied in EOC.
We have previously shown, in cell lines and ovarian
cancer cells from ascites, that inhibitors of glycolysis can
potentiate the effects of different chemotherapeutics,
including platinum compounds [11,12]. In the present
study we investigated the mRNA and protein expression
of GAPDH, PKM2 and ATP5B in 56 advanced serous or
endometrioid ovarian cancers, to test their ability to
predict length of platinum-free interval and survival.
We also assessed, at the mRNA-level, the prognostic
significance of the BEC-index.
Methods
Patients
We prospectively collected fresh tumor specimens from
patients undergoing surgery for epithelial ovarian, fallopian
tube or primary peritoneal cancer. Patients were operated
at Karolinska University Hospital, Stockholm, Sweden,










Figure 1 Flow Chart.consent and the Ethics Committee at Karolinska Institutet,
Stockholm, approved the study.
Tumor and, if present, ascites samples were obtained
from 123 patients of which 62 fulfilled the study’s inclusion
criteria, i.e. age ≥ 18 years, FIGO stage IIC-IV serous or
endometrioid ovarian, fallopian tube or primary peritoneal
cancer (Figure 1). Also, patients had to be scheduled for
platinum-based chemotherapy. Tumors were classified and
graded according to WHO standards [13]. Patient baseline
characteristics, treatment and relapse data were prospect-
ively collected in Case Report Forms (CRFs). All but four
patients underwent primary debulking surgery aiming at
cytoreduction to microscopic disease. In the remaining
cases only biopsy sampling was done. At the time of study,
the staging procedure for ovarian cancer did not include
lymphadenectomy.
Tumor sample collection, processing and RNA extraction
The collection and processing of fresh tumor biopsies has
been previously described in detail [14]. For solid tumor
specimens, imprints were prepared for pathological review.
Only samples with ≥ 50% tumor cells were included in the
study, and five of 62 cases were thus excluded. We did
smear preparations to assess tumor cell yield from ascites,
with the same cut-off of 50% tumor cells as for biopsies.
Ascites samples were processed using the Lymphoprep™Non epithelial ovarian/other        
malignancy, n=12
Other epithelial subtypes, n=8
Borderline tumors, n=13
EOC stage I-IIB, n=14
Benign lesions, n=11
< 50% tumor cells, n=5
< 1.5 µg RNA, n=1
Non platinum-based treatment
n=3
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method [15] for enrichment of tumor cells. We used the
RNeasy Midi Kit™ (Qiagen, Hilden, Germany) for RNA
extraction. RNA quality was assessed using Bioanalyzer
2100 (Agilent Technologies, Santa Clara, CA). An adequate
quantity (≥1.5 μg) and quality (RIN 8–10) RNA could be
extracted in all but one case. Thus, the present study
population consists of 56 patients (Figure 1). In five cases
the RNA yield from the ascites sample was better than that
from the corresponding solid tumor, and therefore used in
the analysis.Real-time PCR
RNA was reverse transcribed by Superscript III (Invitrogene
AB, Stockholm, Sweden). We used the ABI 7500 computer-
ized system (Applied Biosystems, Foster City, CA) and
SYBR Green™ for amplification reactions. Relative quantity
expression values were calculated by the ΔΔCt method
using GenEx software (MultiD, Gothenburg, Sweden).
Primer sequences are listed in Additional file 1. HPRT1
(hypoxanthine guanine phosphoribosyltransferase 1)
and Β2-microglobulin were used as reference genes.
Universal Human Reference RNA (Stratagene, Santa
Clara, CA) served as positive control. Due to technical
failure in one case, PCR analyses were performed in 55
of 56 tumor samples.
For analyses of GAPDH, PKM2 and ATP5B real-time
PCR results, we divided cases into three equally sized
groups according to their relative quantity of mRNA
expression, and the group with lowest expression (one
third of patients, n = 18) was then compared to cases
with higher expression (two thirds of patients, n = 37). A
cut-off at one third was chosen because it approximates
the proportion of patients still alive at median follow-up.
The BEC-index was calculated, at the mRNA-level, by
dividing the ATP5B:HSP60 ratio with the GAPDH
expression value. For this, we used recently published
real-time PCR data for HSP60 mRNA [14]. The third of
cases with the highest BEC-index value (n = 19) was
compared to cases with lower values (n = 36).Immunohistochemistry
Formalin-fixed, paraffin-embedded tumor blocks could be
obtained in 54 of 56 cases. Immunohistochemistry was
performed as previously described [14]. In brief, follo-
wing heat-induced antigen retrieval, primary antibodies
(Additional file 2) were incubated at 8° overnight. Reaction
products were visualized using the Vectastain Elite ABC
kit (Vector Laboratories, Burlingame, CA). Negative
controls were produced by omission of the primary
antibody. A breast carcinoma specimen served as positive
control for GAPDH and PKM2, and for ATP5B a colon
carcinoma sample was used.Three observers (EH, SE and JC), blinded for clinical
data, independently evaluated all slides by assessing the
whole tumor area. The maximum staining intensity of
tumor cells was scored 0-3+, and the percentage of
cancer cells thus stained estimated. Cases were dichoto-
mized into low and high expression groups. Cut-offs
were set arbitrarily to make groups equally sized; for
GAPDH: low expression, 1+ or < 50% of tumor cells
staining 2+, and high expression, 3+ or ≥ 50% staining 2+,
for PKM2: low, 1-2+ or < 20% of tumor cells staining 3+,
and high, ≥ 20% staining 3+, and for ATP5B: low, stain-
ing intensity of tumor cells 1-2+, and high, staining
intensity 3+ (regardless of proportion). Discrepancies
between observers were found for 13% of examined
GAPDH-slides, 6% of PKM2-slides and 15% of ATP5B-
slides, in which cases consensus was reached on further
review.
Statistics
Statistical analyses were performed using STATA 11.2 soft-
ware. The platinum-free interval (PFI) was defined as the
time interval from last course of primary platinum-based
chemotherapy (end of treatment, EOT) to documented
disease progression, death, or last follow-up. Overall
survival (OS) was defined as the time from diagnosis to
death or last follow-up. We estimated PFI and OS by the
Kaplan-Meier method [16] and curves were compared
using Wald’s test. Cox proportional hazards regression
models [17], adjusted for standard confounding risk
factors age, stage, grade and postoperative residual tumor,
were used for multivariate analyses. P-values below 0.05
were considered statistically significant.
Results
Patients
Patients were monitored until 31 March 2011 with a
median follow-up of 59.9 (30.2-82.8) months. Clinical and
pathological characteristics are presented in Table 1.
Over 85% of patients had poorly differentiated (grade 3)
carcinomas, and 89% had FIGO stage IIIC-IV disease. In
70% of cases the postoperative tumor residuals measured
at least 10 mm. All patients received platinum-based
chemotherapy. Of 49 evaluable patients (with measurable
disease at start of chemotherapy), 82% responded to
treatment. Relapse within 6 months from EOT was
detected in 25 of 56 cases (45%). Median PFI was
7.2 months, and median OS 34.6 months. At study clos-
ure, 19 patients (34%) were alive, with no evidence of
disease in 9 cases (16%).
GAPDH
Eighteen patients had a tumor GAPDH mRNA expres-
sion of less than 0.25, and 37 cases expressed at least
0.25 relative to reference genes and positive control.
Table 1 Clinical characteristics of 54 patientsa in relation to immunohistochemical staining for GAPDH, PKM2 and
ATP5B
GAPDH PKM2 ATP5B
n = 54 n = 54 n = 54
Characteristic low <50% 2+ high ≥50% 2+ low <20% 3+ high ≥20% 3+ low 1-2+ high 3+
n = 26 n = 28 n = 26 n = 28 n = 26 n = 28
N (%) N (%) N (%) N (%) N (%) N (%)
Age at diagnosis (years)
Median 64.5 (39–83) NA NA NA NA NA NA
Diagnosis
Epithelial ovarian (n = 41) 22 (54) 19 (46) 23 (56) 18 (44) 21 (51) 20 (49)
Fallopian tube (n = 10) 4 (40) 6 (60) 4 (40) 6 (60) 4 (40) 6 (60)
Peritoneal (n = 3) 0 3 (100) 0 3 (100) 1 (33) 2 (67)
FIGO stage
IIC (n = 2) - IIIB (n = 3) 2 (40) 3 (60) 1 (20) 4 (80) 5 (100) 0
IIIC (n = 42) 21 (50) 21 (50) 21 (50) 21 (50) 18 (43) 24 (57)
IV (n = 7) 3 (43) 4 (57) 4 (57) 3 (43) 3 (43) 4 (57)
Subtype
Serous (n = 47) 22 (47) 25 (53) 19 (40) 28 (60) 23 (49) 24 (51)
Endometrioid (n = 7) 4 (57) 3 (43) 7 (100) 0 3 (43) 4 (57)
Grade of differentiationb
High (n = 4) 2 (50) 2 (50) 1 (25) 3 (75) 2 (50) 2 (50)
Moderate (n = 4) 2 (50) 2 (50) 2 (50) 2 (50) 2 (50) 2 (50)
Poor (n = 46) 22 (48) 24 (52) 23 (50) 23 (50) 22 (48) 24 (52)
Postop residual tumor size
0 mm (n = 6) 3 (50) 3 (50) 0 6 (100) 4 (67) 2 (33)
1-10 mm (n = 10) 4 (40) 6 (60) 3 (30) 7 (70) 5 (50) 5 (50)
>10 mm (n = 38) 19 (50) 19 (50) 23 (61) 15 (39) 17 (45) 21 (55)
1st line Chemotherapy
Carboplatin + paclitaxel (n = 47) NA NA NA NA NA NA
Other platinum based (n = 7)
Time from EOT to recurrence/progression
< 6 months (n = 25) 10 (40) 15 (60) 13 (52) 12 (48) 8 (32) 17 (68)
≥ 6 months (n = 28) 16 (57) 12 (43) 13 (46) 15 (54) 17 (61) 11 (39)
Unknown (n = 1) 0 1 (100) 0 1 (100) 1 (100) 0
Survival
Alive, no evidence of disease (n = 8) 4 (50) 4 (50) 2 (25) 6 (75) 6 (75) 2 (25)
Alive, with disease (n = 9) 6 (67) 3 (33) 4 (44) 5 (56) 5 (56) 4 (44)
Death from disease (n = 36) 16 (44) 20 (56) 19 (53) 17 (47) 14 (39) 22 (61)
Death from other cause (n = 1) 0 1 (100) 1 (100) 0 1 (100) 0
Abbreviations: FIGO, Federation Internationale de Gynecologie et d’Obstetrique, EOT, End of treatment, NA, Not applicable.
aTumor blocks could be retrieved in 54 of 56 cases.
bGrade of differentiation according to WHO international histological classification of tumors.
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mRNA expression, are shown in Figure 2A and B. The
median PFI was significantly shorter in the group with
high expression compared to the low expression group(5.0 and 10.1 months, respectively, p = 0.031). Table 2
shows uni- and multivariate analyses of PFI and OS. In
univariate analysis, high GAPDH mRNA expression was
associated with shorter PFI (HR 2.1, 95% CI 1.1-4.0,
Figure 2 Platinum-free interval (PFI) and overall survival (OS) according to GAPDH and BEC-index mRNA expression. Kaplan-Meier curves
for GAPDH (A and B) and BEC-index based on mRNA (C and D). Patients with high GAPDH had shorter PFI (p = 0.031) and OS (p = 0.015),
whereas patients with high BEC-index had longer PFI (p = 0.028) and OS (p = 0.033).
Table 2 Uni- and multivariate analyses
Expression Univariate analysis Multivariate analysisa
HR (95% CI) p HR (95% CI) p
GAPDH PFI low (<0.25), n = 18 1 1
high (≥0.25), n = 37 2.1 (1.1-4.0) 0.031 2.1 (1.0-4.5) 0.043
OS low (<0.25), n = 18 1 1
high (≥0.25), n = 37 2.8 (1.2-6.5) 0.015 2.3 (1.0-5.6) 0.063
PKM2 PFI low (<0.70), n = 18 1 1
high (≥0.70), n = 37 1.2 (0.7-2.3) 0.55 1.5 (0.8-2.8) 0.27
OS low (<0.70), n = 18 1 1
high (≥0.70), n = 37 1.1 (0.5-2.2) 0.87 1.2 (0.6-2.6) 0.60
ATP5B PFI low (<0.31), n = 18 1 1
high (≥0.31), n = 37 1.7 (0.9-3.3) 0.089 1.8 (0.9-3.6) 0.097
OS low (<0.31), n = 18 1 1
high (≥0.31), n = 37 2.6 (1.1-5.9) 0.025 2.3 (1.0-5.3) 0.062
BEC-index PFI low (≤2.65), n = 36 1 1
high (>2.65), n = 19 0.46 (0.23-0.92) 0.028 0.47 (0.23-0.95) 0.035
OS low (≤2.65), n = 36 1 1
high (>2.65), n = 19 0.42 (0.20-0.94) 0.033 0.49 (0.22-1.31) 0.088
Abbreviations: HR, hazard ratio, CI, confidence interval.
aMultivariate model with adjustment for age, FIGO stage, grade and postoperative residual tumor size.
Platinum-free interval (PFI) and overall survival (OS) in relation to mRNA expression of GAPDH, PKM2, ATP5B and BEC-index.
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multivariate analysis, high GAPDH mRNA remained
significant for shorter PFI (HR 2.1, 95% CI 1.0-4.5, p =
0.043) but not for OS (HR 2.3, 95% CI 1.0-5.6, p =
0.063).
GAPDH protein expression by IHC was low in 26 and
high in 28 of 54 cases (Table 1, Figure 3). GAPDH-
reactivity was predominantly cytoplasmatic, but in 22
cases (41%) we also found nuclear localization of the en-
zyme. There were no statistically significant differences
in PFI or survival between groups with high- or low
GAPDH protein expression (data not shown).PKM2
Eighteen patients had a tumor PKM2 mRNA expression
of less than 0.70, and 37 cases had higher mRNA expres-
sion. There were no statistically significant differences in
PFI or survival between groups with high or low mRNA
expression (Table 2).
Twenty-six cases had low PKM2 protein expression and
in 28 cases the expression was high (Table 1, Figure 3).
The assessed PKM2-reactivity was cytoplasmatic, but in
11 cases (20%) nuclear localization of the protein was
observed in mitotic cells. The immunoreaction does not
provide any information whether the enzyme present is in
its dimeric or more glycolytically active tetrameric form.
There were no statistically significant differences in PFI or
survival between high and low PKM2 protein expressing
groups.Figure 3 Immunohistochemical staining for GAPDH, PKM2 and ATP5B
shows high and low PKM2-reactivity and C and F exemplifies high and lowATP5B
Eighteen patients had a tumor ATP5B mRNA expression
of less than 0.31, and in 37 cases the mRNA expression
was higher. Uni- and multivariate analyses of PFI and
OS are shown in Table 2. In univariate analysis, high
ATP5B mRNA expression predicted poor OS (HR 2.6,
95% CI 1.1-5.9, p = 0.025), but it did not remain signifi-
cant in multivariate analysis (HR 2.3, 95% CI 1.0-5.3,
p = 0.062).
Twenty-six cases had low ATP5B protein expression
and in 28 cases the expression was high (Table 1, Figure 3).
ATP5B-reactivity was cytoplasmatic and often granular.
In univariate analysis, a high ATP5B protein expression
predicted short PFI (HR 1.9, 95% CI 1.0-3.4, p = 0.039),
but it did not reach significance in the multivariate model
(data not shown).BEC-index
Thirty-six patients had an mRNA-based tumor BEC-
index of ≤ 2.65 and 19 cases had higher expression.
Kaplan-Meier curves for PFI and OS, based on BEC-
index mRNA expression, are shown in Figure 2C and D.
The median PFI was significantly longer in the group
with high compared to the group with low BEC-index
(9.8 and 5.3 months, respectively, p = 0.028). Table 2
shows uni- and multivariate analyses for PFI and OS.
Multivariate analysis showed a high BEC-index mRNA
to independently predict longer PFI (HR 0.47, 95% CI
0.23-0.95, p = 0.035). Also, univariate analysis indicated. A and D shows examples of high and low GAPDH-reactivity, B and E
ATP5B-reactivity. Bar = 100 μm.
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CI 0.20-0.94, p = 0.033), but it did not remain significant
in multivariate calculations.
Discussion
Our data indicate that high GAPDH as well as low BEC-
index based on mRNA are associated with early disease
progression in patients with advanced high-grade serous
adenocarcinomas of the ovary, fallopian tube or periton-
eum. To our knowledge, no other study has investigated
the prognostic impact of these markers in ovarian cancer.
GAPDH, a tetramer of four identical 37-kDa subunits,
is a key glycolytic enzyme present in all tissues. It has
commonly been used as a house-keeping reference gene/
protein for expression analyses. However, this practice
has recently been challenged due to findings of GAPDH
playing a role in cancer pathogenesis. In a recent review
GAPDH expression was reported deregulated in e.g.
cancers of the lung, breast, colon, pancreas, liver, kidney
and prostate [18].
In agreement with our results, Révillion and co-workers
reported reduced OS and relapse-free survival among
breast cancer patients with enhanced GAPDH mRNA
expression as assessed by real-time PCR [19]. The study
included 404 unselected breast cancer patients with a
median follow-up of 82 months. In multivariate analyses,
GAPDH was not an independent prognostic factor, but its
expression was inversely correlated to oestradiol and
progesterone receptor concentrations, young age and
grading. Thus, GAPDH mRNA expression in breast cancer
seems to reflect tumor aggressiveness. In the present study,
GAPDH mRNA expression was an independent marker
for early tumor progression in a cohort of ovarian cancer
patients with poor prognosis. Also, our results demonstrate
that GAPDH should not be used as reference RNA in
ovarian cancer.
In contrast to a recently published study in breast
cancer we found no association between GAPDH protein
expression and platinum-free interval or OS. Descotes
et al. used 2D-electrophoresis and Western blotting in 41
node-negative breast cancers of which 20 had metastatic
relapse and 21 had no metastatic recurrence [6]. The
former group had significantly higher GAPDH expression.
Both our studies are based on small cohorts and should
be considered as exploratory. In addition to tumor type,
the methodological approaches also differed. There are
several possible biological explanations to the apparent
discrepancy between our GAPDH mRNA and protein
data, e. g. posttranslational regulation. A plausible reason
can also be the limited sensitivity of immunohistochemis-
try, which requires major differences in expression for
visual detection.
Taking both glycolytic and oxidative capacity into
account, a low BEC-index has been shown to predictshorter survival in colon, lung and breast carcinomas
[3,9,10]. Although we used mRNA instead of protein
expression data, the results of the present study in ovarian
cancer are in accordance with these reports. Apart from
GAPDH and ATP5B, the BEC-index is also influenced
by the expression of the mitochondrial multifunctional
chaperone HSP60. We have earlier shown HSP60 overex-
pression to predict poor outcome in serous ovarian cancer
[14], and the BEC-index data from the present study prob-
ably reflects both the tumor material’s GAPDH and HSP60
expression.
ATP5B-expression per se has also been investigated, but
the results seem contradictory. At the protein level, high
ATP5B has been shown to predict longer survival in colon
cancer [3,20]. In contrast, it was found overexpressed [21]
and associated with poor survival [10] in breast cancer. In
the present study, high ATP5B mRNA expression in ovar-
ian cancer was associated with worse OS, but was not
found to have independent prognostic importance in multi-
variate analysis (p = 0.062).
PKM2 has been linked to poor survival in signet ring
cell cancer and to advanced stage in colorectal cancer
[7,8]. However, the results from our work indicate that
PKM2 might not provide prognostic information in
ovarian cancer.
The mechanisms by which the deregulated metabolic
enzymes in cancer mediate the observed poor prognosis
are complex. Rapidly proliferating cells have a high
demand for energy and glycolytic intermediates for ana-
bolic processes. Some glycolytic enzymes also directly
participate in pathways of proliferation and apoptosis
[22-24]. In addition, PKM2 has been implicated in
platinum-resistance in ovarian cancer cell lines [25], and
down-regulation of ATP5B protein expression has in vitro
been shown to induce 5-FU-resistance in colon cancer [26].
However, targeting breast cancer cell lines with ATP5B-
inhibitor Aurovertin B decreases proliferation [21].
We present a homogeneous clinical material of advanced,
mainly high-grade serous cancers, in which all patients had
peritoneal spread. In this uniform cohort with dismal prog-
nosis, GAPDH and BEC-index mRNA could distinguish
groups with different time to relapse. In line with this, other
studies have supported the notion that there are different
subpopulations of high-grade serous carcinomas [14,27].
This study is limited by its small size, so our results
cannot be generalized to all patients with advanced serous
carcinomas. Its strengths are the prospective study design
and application of CRFs for collection of data. We also used
fresh tumor samples to minimize analytical errors and our
statistical analyses were adjusted for known risk factors.
Conclusions
Our findings indicate that GAPDH and BEC-index may
identify groups of advanced high-grade serous carcinomas
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these results into clinical practice, validation in large
independent cohorts is needed. Targeting metabolic
enzymes could be a future strategy to improve survival
in this group of patients with poor prognosis.
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